Safinamide
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Safinamide: From Parkinson’s Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Safinamide is a MAO-B inhibitor publicly known for use as adjunctive therapy in Parkinson’s disease, though detailed original-indication and mechanism-of-action data are missing from this dataset. The TxGNN model predicts it may be effective for Rasmussen Subacute Encephalitis, but this prediction is currently supported by no clinical trials and no published literature — it is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in dataset (publicly known: Parkinson’s disease, MAO-B inhibitor adjunctive therapy) |
| Predicted New Indication | Rasmussen Subacute Encephalitis |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this dataset. Based on publicly known pharmacology, Safinamide is a reversible MAO-B inhibitor that also blocks voltage-dependent sodium/calcium channels and inhibits glutamate release; it is approved as adjunctive therapy for Parkinson’s disease.
Rasmussen subacute encephalitis is a chronic, focal, immune/excitotoxicity-mediated encephalitis. In theory, glutamate-release inhibition could offer some neuroprotective effect in this setting, which may explain the high TxGNN association score (0.996). However, this link is a mechanistic extrapolation only — there is no direct preclinical or clinical evidence connecting Safinamide to this indication, and the connection rests entirely on the knowledge-graph prediction rather than experimental data.
Two other candidates were predicted with similar characteristics: Myelitis (score 0.995) — a plausible but unproven extension of the same glutamate-inhibition hypothesis — and PLA2G6-associated neurodegeneration (score 0.992), which has somewhat stronger mechanistic plausibility due to shared nigral degeneration and movement-disorder pathology with Parkinson’s disease. All three remain at the model-prediction-only stage (S0).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
Safinamide is currently not marketed in India, with no registered authorizations on file (0 licenses). No product-level registration data is available for review.
Safety Considerations
Drug Interactions: A total of 110 documented interactions were identified. Notable examples include:
| Interacting Drug | Severity | Source |
|---|---|---|
| Bupropion | Major | ddinter |
| Isometheptene | Moderate | ddinter |
| Chlorpropamide | Moderate | ddinter |
| Diethylpropion | Moderate | ddinter |
| Empagliflozin | Moderate | ddinter |
| Phentermine | Moderate | ddinter |
| Glimepiride | Moderate | ddinter |
| Metoclopramide | Moderate | ddinter |
| Repaglinide | Moderate | ddinter |
| Rosuvastatin | Moderate | ddinter |
(Full list contains 110 entries, predominantly insulin/insulin-analogue and sulfonylurea interactions consistent with MAO-B inhibitor–related hypoglycemic risk; Bupropion is the only Major-severity interaction identified.)
Key warnings and contraindications are not available in this dataset — please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by a TxGNN model score (L5, S0 stage), with zero clinical trials and zero published literature. Combined with the absence of original indication/MOA data and no current India market presence, there is insufficient evidence to advance this candidate.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action from DrugBank or primary literature — currently a High-severity data gap
- Preclinical or case-level evidence directly linking Safinamide to Rasmussen encephalitis, myelitis, or PLA2G6-associated neurodegeneration
- Assessment of route/formulation compatibility for the new indication once evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.